“This financing brings us a long way toward meeting our funding goals and putting us in position to go forward with our phase II trials upon receipt of FDA approval of our current protocol,” said Dr Michael Kanovsky, president of Amazon.
The company has submitted to the FDA its protocol to test AMZ0026 as an antiviral and immuno-modulating agent in non-treated HIV subjects.
The study design includes non-symptomatic HIV subjects who are not yet treated with highly active anti-retroviral therapy (HAART), with 50% of the subjects receiving placebo and 50% receiving AMZ0026. The six-month study will include the monitoring of T Cell increases and HIV plasma viral load decreases.